Galavit, 50 mg 5 pcs.

Pharmacotherapeutic group:
Immunomodulatory and anti-inflammatory agent.
ATC code: L03, G02.
Pharmacological properties
Pharmacodynamics
The mechanism of action of the drug is associated with its ability to regulate the functional and metabolic activity of cells of innate and adaptive immunity (monocytes, macrophages, neutrophils, natural killers, etc.). Galavit normalizes phagocytic activity of monocytes/macrophages, bactericidal activity of neutrophils and cytotoxic activity of NK-cells. At the same time restoring the reduced activity of innate and adaptive immunity cells, the preparation increases resistance of the organism to infectious diseases.
Besides, Galavit normalizes antibody formation, indirectly stimulates production of endogenous interferons (IFN-α, IFN-γ), increases functional activity (affinity) of antibodies.
In inflammatory diseases the drug reversibly inhibits excessive synthesis of tumor necrosis factor-α, interleukin-1, interleukin-6 and other pro-inflammatory cytokines for 6-8 hours. Their level determines the degree of inflammatory reactions, their cyclic pattern as well as severity of intoxication.
Galavit decreases production of reactive oxygen species by hyperactivated macrophages, thereby reducing the level of oxidative stress and protecting tissues and organs from the damaging effects of radicals.
Normalization of excessively high functional activity of phagocytic cells leads to the restoration of their antigen-presenting and regulatory function, reducing the level of autoaggression.
The drug has no allergic, mutagenic, embryotoxic, teratogenic and carcinogenic action.
Pharmacokinetics
It is eliminated from the body mainly through the kidneys. After intramuscular injection half-life is 30-40 minutes. The main pharmacological effects are observed within 72 hours.

Indications

As an immunomodulatory and anti-inflammatory agent in the complex therapy of immunodeficiency conditions in adults and adolescents from 12 years of age:
– infectious and inflammatory urogenital diseases (urethritis of chlamydial and trichomonas etiology, chlamydial prostatitis, acute and chronic salpingoophoritis, endometritis);
– purulent-inflammatory diseases of the pelvic organs;
– chronic recurrent diseases caused by the herpes virus;
– diseases caused by the human papillomavirus;
– postoperative rehabilitation of patients with uterine fibroids;
– complications of the postoperative period in women of reproductive age;
– postoperative purulent-septic complications and their prevention (including in cancer patients);
– chronic recurrent furunculosis, erysipelas;
– inflammatory diseases of the mucous membrane of the mouth and throat, periodontal diseases;
– peptic ulcer of the stomach and duodenum;
– viral hepatitis;
– asthenic conditions, neurotic and somatoform disorders, decreased physical performance (including among athletes); mental, behavioral and post-withdrawal disorders in alcohol and drug addiction.
In adults and adolescents from 12 years of age in monotherapy:
– chronic urogenital infections, including during immunorehabilitation measures during the inter-relapse period in order to maintain clinical remission;
– acute and chronic infectious and inflammatory diseases of the gastrointestinal tract, accompanied by intoxication and/or diarrhea.
As an immunomodulatory and anti-inflammatory agent in the complex therapy of immunodeficiency conditions in children over 6 years of age:
– frequent recurrent diseases of the respiratory tract and ENT organs of bacterial and viral etiology (frequent ARVI, bronchitis, pneumonia, chronic tonsillitis, chronic otitis media, chronic adenoiditis).
– purulent surgical diseases (burn lesions, recurrent furunculosis, chronic osteomyelitis, gangrenous appendicitis with omentitis, peritonitis, purulent pleurisy).

Pharmacological effect

Pharmacotherapeutic group:
Immunomodulatory and anti-inflammatory agent.
ATX code: L03, G02.
Pharmacological properties
Pharmacodynamics
The mechanism of action of the drug is associated with its ability to regulate the functional and metabolic activity of innate and adaptive immune cells (monocytes, macrophages, neutrophils, natural killer cells, etc.). The drug Galavit normalizes the phagocytic activity of monocytes/macrophages, the bactericidal activity of neutrophils and the cytotoxic activity of NK cells. At the same time, by restoring the reduced activity of innate and adaptive immune cells, the drug increases the body’s resistance to infectious diseases.
In addition, the drug Galavit normalizes antibody formation, indirectly stimulates the production of endogenous interferons (IFN-α, IFN-γ), and increases the functional activity (affinity) of antibodies.
In inflammatory diseases, the drug reversibly inhibits for 6-8 hours the excessive synthesis of tumor necrosis factor-α, interleukin-1, interleukin-6 and other pro-inflammatory cytokines by hyperactivated macrophages, the level of which determines the degree of inflammatory reactions, their cyclicity, as well as the severity of intoxication of the body.
The drug Galavit reduces the production of reactive oxygen species by hyperactivated macrophages, thereby reducing the level of oxidative stress and protecting tissues and organs from the destructive effects of radicals.
Normalization of excessively increased functional activity of phagocytic cells leads to the restoration of their antigen-presenting and regulatory functions, and a decrease in the level of autoaggression.
The drug has no allergenic, mutagenic, embryotoxic, teratogenic or carcinogenic effects.
Pharmacokinetics
It is excreted from the body mainly through the kidneys. After intramuscular injection, the half-life is 30-40 minutes. The main pharmacological effects are observed within 72 hours.

Special instructions

If you miss the next dose of the drug, its subsequent use should be carried out as usual, as indicated in this instruction or recommended by your doctor.
Impact on the ability to drive vehicles and machinery
The use of the drug does not affect the ability to drive vehicles, maintain machinery and other types of work that require increased concentration and speed of psychomotor reactions.

Active ingredient

Sodium aminodihydrophthalazindione

Composition

Active ingredient: sodium aminodihydrophthalazindione – 50 mg

Pregnancy

The use of the drug is contraindicated during pregnancy and breastfeeding.

Contraindications

Hypersensitivity to sodium aminodihydrophthalazindione, pregnancy and breastfeeding, children under 6 years of age.

Side Effects

In rare cases, allergic reactions are possible.
If the patient experiences any adverse reactions listed in the instructions or they get worse, or if the patient notices any other adverse reactions not listed in the instructions, you should inform your doctor.

Interaction

With simultaneous use, it is possible to reduce the course doses of antibiotics. There are no cases of incompatibility with other drugs.

Overdose

No cases of overdose have been reported.

Storage conditions

Store at temperatures from +15ºС to +25ºС in a place protected from light. Keep out of the reach of children.

Shelf life

4 years.
Do not use after the expiration date indicated on the package.

Manufacturer

Selvim, Russia